Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory Acute Myeloid Leukemia: Analysis of 1,892 Patients from HOVON/SAKK and SWOG

Disclosures: The authors declare no competing financial interests.

Contributions: R.B.W., M.O., and E.H.E. contributed to the conception and design of the study. B.L., G.J.O., S.H.P, T.P., M.-C.V., F.R.A., and H.P.E. contributed to the provision of study material, patient recruitment, and acquisition of data. M.O. participated in the collection and assembly of data. R.B.W., M.O., F.R.A., and E.H.E. participated in the data analysis and interpretation. R.B.W., M.O., and E.H.E. participated in drafting of the manuscript. All authors revised the manuscript critically, and gave final approval to submit for publication.